| Drug General Information |
| Drug ID |
D0VA2I
|
| Former ID |
DCL000095
|
| Drug Name |
CRx-191
|
| Indication |
Psoriatic disorder [ICD9: 696; ICD10:L40]
|
Discontinued in Phase 2 |
[1]
|
|---|
| Company |
CombinatoRx
|
| Target and Pathway |
| Target(s) |
Interferon gamma |
Target Info |
Inhibitor |
[2]
|
|---|
| Tumor necrosis factor |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Proteasome
|
|
Cytokine-cytokine receptor interaction
|
|
HIF-1 signaling pathway
|
|
Regulation of autophagy
|
|
TGF-beta signaling pathway
|
|
Osteoclast differentiation
|
|
Antigen processing and presentation
|
|
Jak-STAT signaling pathway
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
Type I diabetes mellitus
|
|
Salmonella infection
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
African trypanosomiasis
|
|
Malaria
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Measles
|
|
Influenza A
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Inflammatory bowel disease (IBD)
|
|
Systemic lupus erythematosus
|
|
Rheumatoid arthritis
|
|
Allograft rejection
|
|
Graft-versus-host diseasehsa04010:MAPK signaling pathway
|
|
NF-kappa B signaling pathway
|
|
Sphingolipid signaling pathway
|
|
mTOR signaling pathway
|
|
Apoptosis
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
Hematopoietic cell lineage
|
|
Fc epsilon RI signaling pathway
|
|
TNF signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Alzheimer's disease
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Pertussis
|
|
Legionellosis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
HTLV-I infection
|
|
Proteoglycans in cancer
|
|
Asthma
|
|
Graft-versus-host disease
|
|
Hypertrophic cardiomyopathy (HCM)
|
|
Dilated cardiomyopathy
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
TCR Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
Leptin Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
IL3 Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
PANTHER Pathway
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Interferon-gamma signaling pathwayP00006:Apoptosis signaling pathway
|
|
Wnt signaling pathway
|
|
Pathway Interaction Database
|
IL27-mediated signaling events
|
|
IL12-mediated signaling events
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
SHP2 signaling
|
|
Regulation of Telomerase
|
|
Glucocorticoid receptor regulatory network
|
|
IL2-mediated signaling events
|
|
IFN-gamma pathway
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
IL23-mediated signaling events
|
|
PDGFR-alpha signaling pathway
|
|
Calcium signaling in the CD4+ TCR pathway
|
|
Downstream signaling in naï
|
|
IL12 signaling mediated by STAT4il27pathway:IL27-mediated signaling events
|
|
Canonical NF-kappaB pathway
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Signaling events mediated by HDAC Class I
|
|
TNF receptor signaling pathway
|
|
Ceramide signaling pathway
|
|
amb2 Integrin signaling
|
|
RXR and RAR heterodimerization with other nuclear receptor
|
|
HIV-1 Nef: Negative effector of Fas and TNF-alpha
|
|
Caspase Cascade in Apoptosis
|
|
Cellular roles of Anthrax toxin
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
Interferon gamma signaling
|
|
Regulation of IFNG signalingR-HSA-381340:Transcriptional regulation of white adipocyte differentiation
|
|
TNFR1-induced proapoptotic signaling
|
|
Regulation of TNFR1 signaling
|
|
TNFR1-induced NFkappaB signaling pathway
|
|
TNFR1-mediated ceramide production
|
|
TNFR2 non-canonical NF-kB pathway
|
|
TNF signaling
|
|
WikiPathways
|
Type II interferon signaling (IFNG)
|
|
Senescence and Autophagy in Cancer
|
|
TGF Beta Signaling Pathway
|
|
Cytokines and Inflammatory Response
|
|
Hypertrophy Model
|
|
Inflammatory Response Pathway
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
IL1 and megakaryotyces in obesity
|
|
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
|
|
Spinal Cord Injury
|
|
Allograft Rejection
|
|
Interferon gamma signaling
|
|
Proteasome Degradation
|
|
Folate Metabolism
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient NetworkWP75:Toll-like receptor signaling pathway
|
|
Monoamine Transport
|
|
SIDS Susceptibility Pathways
|
|
MAPK Signaling Pathway
|
|
EV release from cardiac cells and their functional effects
|
|
FAS pathway and Stress induction of HSP regulation
|
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
Cardiac Hypertrophic Response
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
Aryl Hydrocarbon Receptor
|
|
Apoptosis
|
|
Nanoparticle triggered regulated necrosis
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Adipogenesis
|
|
TNF alpha Signaling Pathway
|
|
TWEAK Signaling Pathway
|
|
Extrinsic Pathway for Apoptosis
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Selenium Micronutrient Network
|
|
Regulation of toll-like receptor signaling pathway
|
|
Matrix Metalloproteinases
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025635) |
|---|
| REF 2 | CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008. |
|---|
